Siludi Pharmaceutical Co., Ltd. (01244): The sole arbitrator ruled to completely dismiss all arbitration claims brought by SELLAS

Zhitongcaijing · 2d ago

Zhitong Finance App News, Siludi Pharmaceutical Co., Ltd. (01244) issued an announcement. The board of directors of the Company is pleased to announce the latest developments in the dispute case involving SELLAS Life Sciences Group, Inc. (SELLAS). The case was fully reviewed by the Hong Kong International Arbitration Centre, covering the entire evidentiary presentation and debate process, and a final ruling was issued after trial by a sole arbitrator.

The sole arbitrator made a final ruling, completely rejecting all arbitration claims brought by SELLAS, and also ruled that SELLAS must bear the total expenses of HK$7.983 million relating to the Company's arbitration. SELLAS is required to pay this amount in full within 14 days from the date the ruling is issued (that is, on or before August 7, 2026); if it fails to pay any arrears in full and on time, the outstanding amount will be charged overdue interest at an annual interest rate of 8%.

The arbitration does not affect the parties' execution of the license agreement. The Company will continue to advance the development and commercialization of the 3D189 in Greater China in accordance with the agreement between the parties.